Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n = 36), before and after treatment with natalizumab.Jan...
CMP (comprehensive metabolic panel)—a group of tests used to evaluate electrolyte balance and the health of your organs Is there anything else I should know? To help diagnose a central nervous system-related illness, a healthcare provider may want to know about recent vaccinations, sickness, co...
CSF testing for other neurologic disorders (e.g. Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis) while promising are not ready for prime time. 展开 关键词: cerebrospinal fluid (CSF) CSF panel subarachnoid haemorrhage (SAH) ...
Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapiesAuthor links open overlay panelDiego Franciotta a, Gianvito Martino b, Elisabetta Zardini a, Roberto Furlan b, ...
Using a panel of seven brain cell-specific biomarkers in cerebrospinal fluid (CSF), pediatric opsoclonus-myoclonus syndrome (OMS) (n= 234) was compared to pediatric non-inflammatory neurological controls (n= 84) and other inflammatory neurological disorders (OIND) (n= 44). Only CSF NFL was ele...
even though most attention has centered around the proportion of analytes which failed to perform up to expectation. Looking across ADNI and other large cohorts’ available biomarker measures relative to their technical performance, the mostly unexplored panel of CSF biomarkers we annotated here — with...
Here, we sought to understand the contributions of proteins downstream of, and potentially orthogonal to, Aβ and tau across the preclinical, prodromal, and dementia stages of AD. We measured a diverse panel of 270 proteins in the CSF and plasma of up to 1022 individuals, using a validated,...
YKL-40 can be detected in cerebrospinal fluid (CSF) and the levels are increased in preclinical and prodromal AD, as well as in other neurodegenerative conditions, such as Frontotemporal Lobar Degeneration (FTLD), Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS)7,8,9,10. Other ...
Such a panel of biomarkers will have two main uses for clinical development of therapeutics: to identify subgroups within a broad clinical diagnosis that can be selected for enrollment in trials for targeted therapies; and as a diagnostic marker for remediation of disease alterations during a course...
HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis...